Indications
Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.
Composition
- Active substance
- tocofersolan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vedrop
- Active substance
- tocofersolan
- ATC code
- A11HA08
- Therapeutic area
- Cholestasis, Vitamin E Deficiency
- Marketing authorisation holder
- Recordati Rare Diseases
- Status